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Purpose: To evaluate the effects of 17-β-estradiol on hyperosmolar stress-induced proinflammatory cytokine production
of interleukin (IL)-6, IL-1, and tumor necrosis factor-alpha (TNF-α) in SV40-immortalized human corneal epithelial cells
(hCECs) and the regulatory effects of the mitogen-activated protein kinase (MAPK) signaling pathways in this process.
Methods: SV40 hCECs cultured in normal osmolar media were switched to a higher osmolarity (450 mOsM) by adding
NaCl with or without pretreatment with 17-β-estradiol. Real-time polymerase chain reaction and ELISA were applied to
characterize  IL-6,  IL-1,  and  TNF-α  gene  and  protein  expression.  Cells  were  treated  for  15−60  min,  lysed  in
radioimmunoprecipitation assay (RIPA) buffer and subjected to a western blot with phospho (p)-specific antibodies against
extracellular signal-regulated protein kinase 1/2 (ERK1/2), P38 kinase, and c-Jun N-terminal kinase 1/2 (JNK1/2).
Results: The expression and production of IL-6, IL-1, and TNF-α in SV40 hCECs increased when the media osmolarity
was switched to 450 mOsM. Pretreatment with 10−10 M 17-β-estradiol greatly inhibited the increased expression and
production of IL-6, IL-1, and TNF-α induced by hyperosmolarity, whereas with the administration of SB203580 (10
μM), an inhibitor of the p38 pathway, the inhibiting effect of 17-β-estradiol disappeared. The western blot results showed
that the increased phosphorylation level of p38 caused by hyperosmolarity was greatly inhibited by 17-β-estradiol.
Conclusions: 17-β-estradiol greatly inhibited the expression and production of proinflammatory cytokines IL-6, IL-1,
and TNF-α, which were stimulated by hyperosmolarity in SV40-immortalized hCECs. The results also suggested that the
p38 MAPK signaling pathway was involved in the regulatory effects of estrogen on hCECs. These findings may contribute
to an understanding of the etiologic roles and therapeutic implications of the hormone estrogen in dry eye disease.
Dry eye disease (DED) is among the most common and
problematic conditions confronted by ophthalmologists. Most
epidemiologic studies have demonstrated a higher prevalence
of  dry  eye  syndrome  in  the  elderly,  especially  in
postmenopausal women [1-3]. The significant gender-based
differences in the incidence of dry eyes suggest that estrogens
play an important role in DED. Although many studies have
produced evidence of estrogen receptors in ocular surface
tissues [4,5], the mechanism by which estrogens influence the
ocular surface is not yet clear. Jensen et al. [6] reported that
hormone  replacement  therapy  (HRT)  in  postmenopausal
women  may  help  alleviate  symptoms  related  to  ocular
dryness.  However,  a  randomized  trial  showed  no  strong
evidence  to  support  the  use  of  HRT  for  treating  dry  eye
syndrome  [7],  and  Schaumberg  et  al.  [8]  suggested  that
women who use HRT, particularly estrogen alone, are at an
increased risk of DED. Such controversies regarding the risks
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and benefits of estrogen therapy on dry eyes highlights the
complex role of sex hormones in ocular surface health and the
need for further study.
Recent studies have suggested that hyperosmolarity is a
key factor in the pathogenesis and diagnosis of DED. The
inadequate secretion of tears and increased tear evaporation,
either of which results in hyperosmolarity, are two major
causes of DED [9]. The normal osmolarity of the tear fluid is
approximately 300 mOsm/kg [10] and the suggested “gold
standard” referent for the diagnosis of DED is 316 mOsm/kg
or greater [11,12]. Two common mechanisms contributing to
the pathogenesis of ocular surface injury in DED are tear
hyperosmolarity and ocular surface inflammation [13]. There
is  increasing  evidence  that  tear  hyperosmolarity  triggers
ocular surface inflammation cascades [14]. Liu et al. [15] also
reported that people subjected to the instillation of NaCl and
sucrose  hyperosmolar  drops  complained  of  dry  eye
discomfort.  Furthermore,  hyperosmolar  media-cultured
hCECs have been widely used to study the pathogenesis of
and  therapeutic  interventions  that  may  alleviate  DED
[16-18].
A  previous  research  has  investigated  the  effects  that
estrogen may have on the corneal epithelial cells in cases of
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1115DED [19]. However, much of this work was performed in an
isosmotic  environment  that  did  not  perfectly  simulate  the
pathological  changes  on  the  cornea  in  cases  of  DED.
Furthermore, the previous study rarely examined the signaling
pathways to clarify the underlying mechanisms. Therefore,
the purpose of the current study was to investigate the effects
of  estrogen  on  hyperosmolarity-stressed  hCECs  and  to
elucidate  the  regulatory  effects  that  the  mitogen-activated
protein  kinase  (MAPK)  signaling  pathways  may  have
involved.
METHODS
Material and reagents: Cell culture dishes, plates, centrifuge
tubes,  and  other  plastic  wares  were  purchased  from  BD
Bioscience (Lincoln Park, NJ). DMEM/Ham’s F12 medium
(50% Dulbecco Modified Eagle Medium and 50% Ham’s
Nutrient  Mixture  F-12),  phosphate  buffered  saline  (PBS),
0.25% trypsin, DNA or RNA size markers, and a random
primer DNA labeling kit were purchased from Invitrogen
Gibco  (Grand  Island  [GIBCO],  NY).  Fetal  bovine  serum
(FBS) was purchased from Hyclone (Logan, UT). Sodium
chloride (NaCl), 17-β-estradiol, dimethyl sulfoxide (DMSO),
ethanol, human recombinant EGF, and all other reagents were
purchased  from  Sigma-Aldrich  (St.  Louis,  MO).
Recombinant  human  interleukin  (IL)-6,  IL-1,  and  tumor
necrosis  factor-alpha  (TNF-α)  enzyme-linked
immunosorbent assay (ELISA) kits (eBioscience, San Diego,
CA)  were  used.  The  other  materials  used  were  phospho-
specific  monoclonal  antibodies  for  extracellular  signal-
regulated  protein  kinase  (ERK),  c-Jun  N-terminal  kinase
(JNK), and p38 kinase and rabbit antibodies from Santa Cruz
Biotechnology (Santa Cruz, CA); nitrocellulose membranes
from Schleicher and Schuell (Keene, NH); SYBR Premix Ex
Taq, Polymerase Chain Reaction (PCR) forward primer, PCR
reverse primer, ROX reference dye and DNA template from
TaKaRa BIO, Inc. (Shiga, Japan).
Culture of hCECs: The Simian virus (SV) 40-immortalized
hCECs were kindly provided by Dr. Zan Pan (State University
of New York, New York, NY) and cultured in DMEM/F12,
which was supplemented with 10% fetal bovine serum and 10
ng/ml  human  recombinant  epidermal  growth  factor.  Cells
were incubated in a CO2-regulated incubator in a humidified
95% air/5% CO2 atmosphere. The medium was renewed every
two days. After the culture reached confluence, cells were
detached with 0.25% trypsin and seeded into 96-well and 24-
well  plates  at  a  density  of  5×103  and  5×105  cells/well,
respectively.
Cell viability assay: After implantation into 96-well plates for
24 h, cells were placed in serum-free medium. 17-β-estradiol
was added at final concentrations of 10−8, 10−9, 10−10, and
10−11  M.  Both  controls  without  17-β-estradiol,  and  17-β-
estradiol-treated cells were incubated for an additional 24 h.
Subsequently, cells were collected and resuspended with 1×
assay buffer at a cell density of 2×105/ml. One hundred μl of
the  cell  suspension  was  labeled  with  Annex-V/propidium
iodide (PI) and analyzed by using flow cytometry (The Becton
Dickinson LSR flow cytometer; Becton Dickinson, Franklin
Lakes, CA).
RNA extraction and real-time PCR: Cells were seeded in 24-
well plates at a density of 5×105 cells/well. After 24 h, the
medium was replaced with a serum-free DMEM/F12 medium.
According to the method of Luo et al. [20], hyperosmolarity
(450 mOsM) was achieved by adding NaCl to reach a final
concentration  of  70  mM.  Cells  were  exposed  to  the
hyperosmotic medium pretreated with 10−10 M 17-β-estradiol
for 40 min. Cells were then collected at different time points
for the measurement of IL-6, IL-1, and TNF-α expression.
Total cellular RNA was isolated by using TRIzol reagent
(Invitrogen,  Carlsbad,  CA).  The  RNA  was  treated  with
Deoxyribonuclease I (Invitrogen) to remove the chromosomal
DNA,  evaluated  spectrophotometrically  at  260  nm  to
determine the concentration, and examined on 1.0% agarose
(GIBCO) gels to confirm RNA integrity. Real-time PCR was
used to confirm the differential expression of the IL-6, IL-1,
and TNF-α genes. Cells cultured in a hyperosmotic medium
without any 17-β-estradiol treatment were used as controls.
Sense  and  antisense  primers  were  designed  using  Primer
Express  Software,  version  1.0  (Applied  Biosystems,  Inc.,
Foster City, CA; Table 1). Real-time PCRs were performed
according  to  the  manufacturer’s  recommendations,  using
10 μl SYBR Premix Ex Taq (2×), 0.4 μl PCR forward primer
(10 μM), 0.4 μl PCR reverse primer (10 μM), 0.4 μl ROX
reference dye II (50×), 2 μl DNA template, 6.8 μl ddH2O in
96-well reaction plates, ABI PRISM optical adhesive covers,
and  the  GeneAmp  7500  sequence  detection  system.  The
amplification program involved 30 s at 95 °C, followed by 40
cycles of 15 s at 95 °C and 3 s at 60 °C. The relative gene
expression was determined by using the 7500 software V2.0.1
(Applied  Biosystems  [ABI],  Foster  City,  CA)  and
standardizing the levels to those of β-actin (ACTB) mRNA.
Dissociation curves were evaluated to ensure the absence of
secondary PCR products.
IL-6, IL-1, and TNF-α measurements: Cells were seeded in
24-well plates at a density of 5×105 cells. After 24 h, the
medium was replaced with a serum-free DMEM/F12 medium.
Hyperosmolarity (450 mOsM) was achieved by adding NaCl
to reach a final concentration of 70 mM. Cells were exposed
to  the  hyperosmotic  medium,  which  was  pretreated  with
10−10 M 17-β-estradiol with or without SP600125 50 μM (an
inhibitor of the JNK pathway), SB203580 10 μM (an inhibitor
of the p38 pathway), or U0126 10 μM (an inhibitor of the ERK
pathway) for 40 min. The culture medium was then collected
for the measurement of IL-6, IL-1, and TNF-α and compared
with cells cultured in media that had not been pretreated with
17-β-estradiol. All the collected media were centrifuged at
800× g for 5 min, and the supernatants were transferred to
vials and stored at −80 °C until the various cytokines were
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1116measured. The concentrations of IL-6, IL-1, and TNF-α were
measured  in  triplicate  by  using  recombinant  human  IL-6,
IL-1,  and  TNF-α  ELISA  kits  in  accordance  with  the
manufacturer’s  instructions.  Amounts  were  expressed  in
picograms per milliliter (pg/ml).
Western blot analysis: The cells treated for 15–60 min were
lysed in RIPA buffer, and appropriate volumes (20–30 μl) of
cell extracts, adjusted to represent the same amount of total
cellular protein (50 μg), were electrophoresed under reducing
conditions at 4 °C in a 4% to 15% gradient polyacrylamide
gel. After electrophoretic transfer to a nitrocellulose (NC)
membrane at 100 V for 1 h at 4 °C, the membranes were
blocked with 10% nonfat milk in TBST (10mM Tris-HCl,
pH7.5,  150mM  NaCl,  0.05%Tween-20)  for  4  h  at  room
temperature.  The  primary  antibody  (i.e.,  phospho-specific
antibodies against JNKs, ERKs, or p38) in TBST containing
10% nonfat milk was placed on each membrane and incubated
at room temperature for 3 h. After three washings with TBST
over  15  min,  the  second  antibody,  conjugated  with
horseradish  peroxidase  (HRP)  was  applied.  After  three
washings  with  TBST  over  15  min,  the  membrane  was
analyzed by the Odyssey® Infrared Imaging System (LI-COR
Biosciences, Lincoln, NE).
Statistical analysis: Statistical comparisons of control and
treatment groups for real-time PCR and ELISA data were
performed  via  One-way  ANOVA  (statistical  package
SPSS10.0 [SPSS Inc., Chicago, IL]), with p<0.05 considered
to be statistically significant.
RESULTS
Cell viability assay: Flow cytometry (Figure 1) showed that
cultured hCECs treated with 17-β-estradiol at concentrations
of 10−10 M and 10−11 M for 24 h did not show a significant
difference in cell viability as compared with cells cultured
without 17-β-estradiol (Figure 1; control). With the use of 17-
β-estradiol at concentrations of 10−8 M and 10−9 M, the cell
apoptosis percentages were increased to 14.24% and 11.27%,
respectively,  which  suggested  that  treatment  with  17-β-
estradiol at concentrations higher than 10−10 M may have
adverse effects on cell survival. Therefore, we used 10−10 M
17-β-estradiol in all of the following experiments in this study.
Effects  of  estrogen  on  IL-6,  IL-1,  and  TNF-α  mRNA
expression: Real-time PCR analysis revealed that IL-6, IL-1,
and TNF-α mRNA expression was gradually upregulated in a
450  mOsM  hyperosmotic  medium  as  exposure  time  was
prolonged (3−24 h) (Figure 2). The pretreatment with 17-β-
estradiol for 40 min greatly inhibited IL-6, IL-1, and TNF-α
mRNA expression in the early stage of the hyperosmotic
stimulation, and the suppression effect lasted as long as 24 h.
The inhibitory effects of 17-β-estradiol on IL-6, IL-1, and
TNF-α mRNA expression increased with time and at 24 h, the
suppressive  effects  reached  90.1%,  60.9%,  and  68.5%,
respectively.
TABLE 1. OLIGONUCLEOTIDE PRIMERS DESIGNED FOR REAL-TIME PCR.
Primer Orientation Nucleotide sequence (5′-3′) Amplicon size (bp)
IL-1 Sense TGGCGGCATCCAGCTACGAA 247
  Antisense CCGGAGCGTGCAGTTCAGTGA  
IL-6 Sense AGCGCCTTCGGTCCAGTTGC 240
  Antisense TGCCAGTGCCTCTTTGCTGCT  
TNF-α Sense TTCCTGATCGTGGCAGGCGC 246
  Antisense CAGCTCCACGCCATTGGCCA  
ACTB Sense CGTTGACATCCGTAAAGACC 242
  Antisense AACAGTCCGCCTAGAAGCAC  
Figure 1. Effects of 17-β-estradiol on cell viability. Cells were cultured with 17-β-estradiol at different concentrations for 24 h. The percentage
of apoptotic cells were calculated (10−8 M 14.24%; 10−9 M 11.27%; 10−10 M 5.11%; 10−11 M 5.38%, respectively). Statistical analysis showed
that 17-β-estradiol at concentrations of 10−10 and 10−11 M did not show a significant difference (p>0.05) as compared with the controls, cells
cultured without 17-β-estradiol.
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1117Estrogen reduced hyperosmolarity-induced IL-6, IL-1, and
TNF-α production: ELISA was used to determine the effects
of the 40-min pretreatment with 10−10 M 17-β-estradiol on the
hyperosmolarity-induced increases in IL-6, IL-1, and TNF-α
production. At 24 h, IL-6, IL-1, and TNF-α production was
about 2–4 fold greater than that of the control group, without
the 17-β-estradiol pretreatment. At 24 h, IL-6, IL-1, and TNF-
α protein in pretreated cells were as much as 68.65%, 43.68%,
and 62.73% less, respectively, than in cells that had not been
pretreated with 17-β-estradiol (Figure 3). That is, comparing
the  two  groups,  these  proteins  were  present  in  a  smaller
amount in the pretreated cells than in the non-pretreated cells.
These results indicated that IL-6, IL-1, and TNF-α production
was greatly inhibited in the 17-β-estradiol-pretreated cells.
Effects of estrogen on the activation of the MAPK pathway:
Using  phosphor-specific  antibodies,  western  blot  analysis
revealed  that  the  activated  (phosphorylated)  p38  was
dramatically inhibited by pretreatment with 17-β-estradiol in
SV40-immortalized hCECs within 15−60 min of exposure to
450  mOsM  hyperosmolar  media.  In  the  control  group,
stimulated by the hyperosmolarity, p38 began to activate at
the  15  min  time  point,  and  the  maximum  activation  was
observed after 30 min. A similar response was also observed
in the case of p-ERK, with an increase by 15 min and the
maximal activation being reached at 30 min. In the group of
Figure  2.  Real-time  PCR  results  of
IL-6, IL-1, and TNF-α mRNAs. Real-
time PCR results of IL-6, IL-1, and TNF-
α  mRNAs  in  SV40-immortalized
HCECs pretreated with 17-β-estradiol
and exposed to hyperosmolar media for
24  h.  Controls  were  cells  cultured  in
hyperosmolar  media  without
pretreatment with 17-β-estradiol. IL-6,
IL-1, and TNF-α mRNA expression was
gradually upregulated in a 450 mOsM
hyperosmotic medium from 3 to 24 h.
Pretreatment with 17-β-estradiol greatly
inhibited IL-6, IL-1, and TNF-α mRNA
expression  and  the  suppression  effect
lasted as long as 24 h. Similar results
were  obtained  in  three  independent
experiments. *p<0.05, **p<0.01.
Figure 3. ELISA results regarding the
amounts of IL-6, IL-1, and TNF-α in
HCECs.  Pretreatment  with  17-β-
estradiol inhibited the hyperosmolarity-
induced  increases  in  IL-6,  IL-1,  and
TNF-α production. Data are the mean
±SEM  of  the  results  from  three
independent  experiments.  With
pretreatment with 17-β-estradiol, IL-6,
IL-1, and TNF-α production was greatly
inhibited (black box) as compared with
cells  cultured  in  hyperosmolar  media
without pretreated 17-β-estradiol (white
box). *p<0.05, **p<0.01.
Molecular Vision 2012; 18:1115-1122 <http://www.molvis.org/molvis/v18/a118> © 2012 Molecular Vision
1118cells, which were pretreated with 17-β-estradiol, p38, and
ERK were rarely activated by the hyperosmolarity (Figure 4).
However,  there  was  no  difference  in  p-JNK  between  the
pretreated cells and the controls. When inhibitors of the JNK
pathway (SP600125 50 μM), the p38 pathway (SB203580
10 μM), and the ERK pathway (U0126 10 μM) were used,
only the p38 inhibitor SB203580 could suppress the elevation
of cytokines caused by hyperosmolarity (Figure 5). Figure 5
also showed that 17-β-estradiol pretreatment could suppress
hyperosmotic-induced increases in any of the cytokines in all
conditions with or without JNK/ERK/p38 MAPK inhibitors.
Because all three inhibitors of the pathways were dissolved in
DMSO, we used DMSO as a negative control.
DISCUSSION
This  study  demonstrated  that  17-β-estradiol  inhibited  the
expression  of  proinflammatory  cytokines  in  immortalized
hCECs.  17-β-estradiol  pretreatment  caused  a  significant
decrease in the levels of IL-6, IL-1, and TNF-α mRNA as
compared with hyperosmolar media-exposed control cells.
The ELISA data provided further support for the notion that
17-β-estradiol suppresses the production of IL-6, IL-1, and
TNF-α induced by hyperosmolarity at the protein level. Both
of the results showed that the expression of IL-6, IL-1, and
TNF-α remained at a constant low level throughout the entire
course of the experiment. In contrast, the IL-6, IL-1, and TNF-
α levels in the control group were dramatically increased with
time. These results indicated that the efficacy of 17-β-estradiol
could be maintained for an extended period. Furthermore, of
the three inhibitors added to the culture media (SP600125
50 μM for the JNK pathway, SB203580 10 μM for the p38
pathway, and U0126 10 μM for the ERK pathway), SP600125
and U0126 did not inhibit the effect of the hyperosmolarity-
induced elevation of cytokines in cells. Only p38 inhibitor
SB203580 could suppress the elevation of cytokines caused
by hyperosmolarity.
There is growing recognition that inflammation plays an
important  role  in  DED,  and  increased  levels  of
proinflammatory cytokines and markers have been observed
in both the tear films and ocular surface epithelia of patients
with dry eye [21,22]. TNF-α, IL-1, and IL-6 are cytokines that
have been the focus of various studies on DED [23-25]. In our
present study, both the mRNA expression and the protein
production of the three cytokines showed dramatic increases
in response to a hyperosmolar stimulus.
The  ability  of  estrogen  to  inhibit  proinflammatory
cytokines is analogous to the hormone’s action in other sites
of the human body. Elisabetta et al. [26] reported that estrogen
prevented  lipopolysaccharide-induced  inflammatory
response  in  microglia  in  the  central  nervous  system,
demonstrating  a  protective  role  of  estrogen  in
neurodegenerative  disorders  in  humans  and  experimental
animal models. Other evidence has indicated that estradiol
supplementation reduced the production of TNF-α, IL-1β, and
Figure 4. Western blot results of HCECs
cultured  in  450  mOsM  hyperosmolar
media. The western blot shows the time
course of activated phosphorylated p38,
which is apparently inhibited by 17-β-
estradiol in SV40-immortalized human
corneal epithelial cells cultured in 450
mOsM hyperosmolar media.
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1119IL-6 and decreased the activation of p38 MAPK as compared
to their untreated counterparts, which suggested that the effect
of estrogen on cardioprotection may be attributed to its anti-
inflammatory properties [27]. As in our study, similar MAPK
changes were observed in the context of estrogen protection
against hyperosmolarity-induced proinflammatory cytokine
elevation  in  hCECs,  i.e.,  proinflammatory  cytokine
production  was  inhibited  via  the  p38  MAPK  signaling
pathways. The MAPK signaling pathways play an important
role in the cellular response to specific stimuli, and they also
regulate specific substrates [28,29]. MAPKs include JNK, p38
and  ERK.  ERK  is  mainly  involved  in  cell  survival,  cell
proliferation and hyperosmolar stress [30], while p38 and JNK
cascades  are  strongly  activated  by  various  extracellular
stimuli, including changes in osmolarity [31,32]. It is certain
that the MAPK pathways were involved in the elevation of
hyperosmolarity-induced  proinflammatory  cytokines  in
hCECs, but which special pathway of the MAPK pathways
mediates increases in cytokine release during exposure to
hypertonicity is yet unclear. Different literatures have stated
that different MAPK pathways take part in mediating the
increases in cytokine release during exposure to hypertonicity.
Hyperosmolarity’s effects on the activation of MAPK are
highly cell-specific. Selective or combined activation of ERK,
p38 and/or JNK by hyperosmoticity stimulation depends on
the cell type [33].
Using  phosphor-specific  antibodies,  western  blot
analysis revealed that the phosphorylated p38 and ERK were
dramatically activated by hyperosmolar stress and that the
phosphorylation of p38 and ERK was greatly inhibited by
pretreatment with 17-β-estradiol. Our purpose of this research
project was to investigate the specific pathway involved in the
elevation of proinflammatory cytokine. When the inhibitors
of the ERK pathway (U0126 10 μM) and the p38 pathway
(SB203580  10  μM)  were  used,  only  the  p38  inhibitor
SB203580 could suppress the elevation of proinflammatory
cytokines caused by hyperosmolarity. The result of our study
demonstrated that 17-β-estradiol can suppress hyperosmotic-
induced increases in any of the cytokines in all conditions with
or  without  JNK/ERK/p38  MAPK  inhibitors,  while  in  the
absence  of  p38  MAPK  activity  caused  by  exposure  to
SB203580, the effects of hyperosmotic-induced increases in
any of the cytokines were suppressed, which suggested that
the p38 MAPK pathway was involved in the elevation of
hyperosmolarity-induced  proinflammatory  cytokines  in
hCECs. It also indicated that 17-β-estradiol had a somewhat
similar role in the effect of hyperosmotic-induced increases
in the cytokines as that of the p38 MAPK inhibitor. Chen et
al. found that the activation of p38MAP kinase (p38), JNK
MAP kinase (JNK) and NF-kB in cultured corneal epithelial
cells  was  induced  by  hyperosmotic  conditions  [13].
Furthermore,  they  found  that  p38  inhibitor  significantly
suppressed  hyperosmoticity-induced  IL-1b  production,
whereas  JNK  inhibitor  failed  to  do  so.  Therefore,  they
postulated  that  hyperosmoticity-induced  IL-1b  expression
was mainly achieved via the p38 pathway in hCECs. The
situation in our study is to some extent similar to the results
reported by Chen  et al [13]. The  western    blot    showed      that
both p-p38 and p-ERK were greatly suppressed over the time
course and ELISA results showed that inhibiting the ERK
pathway (with U0126 10 μM) did not influence the level of
cytokines. It demonstrated that the ERK signaling pathway
Figure 5. ELISA results regarding the
amounts  of  IL-6,  IL-1,  and  TNF-α
present  with  inhibitors  of  the  MAPK
pathway  in  HCECs.  Inhibitors  of  the
JNK pathway (SP600125 50 μM), the
p38 pathway (SB203580 10 μM), and
the ERK pathway (U0126 10 μM) were
used, but only SB203580 (an inhibitor
of  the  p38  pathway)  suppressed  the
elevation  of  cytokines  caused  by
hyperosmolarity.  17-β-estradiol
suppressed  the  hyperosmoticity-
induced  elevation  of  all  of  the  three
cytokines in conditions with or without
JNK/ERK/p38  MAPK  inhibitors.
**p<0.01.
Molecular Vision 2012; 18:1115-1122 <http://www.molvis.org/molvis/v18/a118> © 2012 Molecular Vision
1120may be activated by the hyperosmolar stimulus and that it
could also be suppressed by the 17-β-estradiol, but this ERK
pathway was not involved in the regulatory effect of estrogen
in the production of proinflammatory cytokines. The ERK
signaling pathway probably participates in some other aspects
of the interactions between estradiol and hyperosmolarity-
stressed hCECs.
It is important to note that our results relate to 17-β-
estradiol  and  the  expression  of  corneal  proinflammatory
cytokines, such as IL-6, IL-1, and TNF-α, in immortalized
cells. Whether such estrogen actions also occur in primary
corneal epithelial cells in vitro or in vivo and are associated
with parallel alterations in the protein and signaling pathways
remains to be determined. However, we processed the cells in
hyperosmolar  media,  which  could  mimic  the  pathological
changes in DED in vivo to a large extent. Many studies have
suggested  that  hyperosmolarity  is  a  key  factor  in  the
pathogenesis and diagnosis of DED. We used 450 mOsM
osmolarity in our experiment because this osmolarity is the
most commonly used osmolarity in dry eye research [17,20,
29]. Tear osmolarity in dry eye patients ranges from 306 to
441 mOsm, with an average of 343 mOsm. However, a recent
study suggests that transiently, tear hyperosmolarity may be
much higher when local tear film thinning or breakup occurs
[34].  Therefore,  the  osmolarity  of  450  mOsM  could  well
reflect  the  hyperosmolarity-induced  proinflammatory
cytokine elevation in human corneal pathogenesis. However,
Suzuki  et  al.  [19]  reported  that  17-beta-estradiol  induced
proinflammatory  cytokines  in  immortalized  hCEC.  The
reason for the discrepancy may be that the previous work was
done in normal condition while our present work was done in
hyperosmolar  condition.  Under  stressful  conditions,  cells
were forced to adapt for survival. When cells were cultured in
hyperosmolar condition, different kinds of protein and gene
expressions might occur, which resulted in divergent reactions
to the stimulus.
Although  the  role  of  estrogen  in  dry  eye  has  been
recognized and the pathologic mechanisms in dry eyes are
being investigated, minimal data are available regarding the
effect  of  pregnancy,  hysterectomy  and  androgens  on  the
ocular surface. The complex role of sex hormones on ocular
surface  health  and  disease  warrants  further  study.
Postmenopausal women are known to have an increased risk
of dry eyes. Lactation (low estrogen state) is also associated
with an increased risk of dry eyes. While pregnancy, oral
contraceptive use, and hormone replacement (a high estrogen
state)  also  result  in  dry  eyes,  these  conflicting  findings
indicated  that  there  may  be  a  balance  among  different
hormones. A thorough understanding of this will help us to
make  appropriate  guidelines  for  hormone  replacement
therapy  to  alleviate  hyperosmolarity-induced  corneal
inflammatory responses in post-menopausal women.
In  conclusion,  17-β-estradiol  greatly  inhibited  the
expression  and  production  of  proinflammatory  cytokines
IL-6,  IL-1,  and  TNF-α,  which  were  stimulated  by
hyperosmolarity via the p38 MAPK signaling pathway in
SV40-immortalized hCECs. These findings may contribute to
the  understanding  of  the  etiologic  roles  and  therapeutic
implications of the hormone estrogen in DED.
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